Vasopressin Plasma Concentrations in Patients Receiving Exogenous Vasopressin Infusion for Septic Shock

Completed

Conditions studied: Septic Shock

In brief

This is a prospective observational cohort trial evaluating a single plasma vasopressin concentration in patients receiving exogenous, adjunctive vasopressin for septic shock. The trial is designed to determine whether plasma vasopressin concentration influences the likelihood of hemodynamic response to exogenous vasopressin therapy.

Key facts

Study ID

NCT03014063

Run by

The Cleveland Clinic

People needed

18

Starts

2016-11-01

Expected to finish

2017-06-01

Last updated by the study team

2019-01-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with septic shock as defined by The Third International Consensus Definitions for Sepsis and Septic Shock
• Patients ≥18 years of age
• Treatment with exogenous vasopressin, as ordered by the primary medical team, at a constant infusion rate for at least 3 hours as an adjunctive vasopressor to catecholamine therapy
• Admission to a medical, surgical, or neurosciences intensive care unit
• Presence of a central venous catheter or arterial line (as determined by the primary medical team)

You may not qualify if…

• Patients treated with vasopressin for indications other than septic shock
• Patients administered vasopressin that is titrated within the first 3 hours
• Patients receiving vasopressin as the sole vasoactive therapy

Where it is running

• Cleveland Clinic — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.